Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS' Sprycel loses out to Novartis' discounted Tasigna in England

This article was originally published in Scrip

Executive Summary

BMS's Sprycel (dasatinib) appears to have lost out to Novartis' Tasigna (nilotinib) as an NHS funded treatment option for chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia (CML) because of cost. NICE, the health technology appraisal body for England and Wales, said a preliminary yes to the Glivec follow-on after Novartis offered a discount. NICE has again endorsed the use of Glivec 400mg, but Bristol-Myers Squibb failed to convince the institute that its competitor drug, Sprycel (dasatinib), would be a cost-effective option.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC015440

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel